Grants Funded

Texas leads the nation in its commitment to the war on cancer. CPRIT has funded 2038 awards for cancer research, product development, and prevention since 2010. The total amount awarded thus far is $3,739,557,155.

Recipients of CPRIT awards include 151 academic institutions, non-profit organizations, and private companies all located in Texas. The research and prevention efforts funded by CPRIT advance the health of Texans, research superiority of the state, life science infrastructure, and the Texas economy. These projects are operating in virtually all regions of the state with Texas-based employees.


Search Instructions

There are two ways to search the grants listed below.

Simple: Enter your search term into the search box above the column you would like to filter, your results will automatically start to filter after you entered the third letter of your search term. For example, to see grants with a title containing coalition, enter "coalition" into the search box above Title.

Multiple: To search for grants that are part of a coalition that focus on colorectal cancer, enter "coalition" into the search box above Title and "colorectal" into the search box above Cancer Type.

Grant IDTitleProgramPrimary Investigator/
Program Director
OrganizationCancer TypesAward DateAward Amount1
CPRIT Funded Grants
DP250135 Personalized Immunotherapy for Recurrent, Resectable Head and Neck Cancer Product Development Research Pack, Christopher Metaclipse Therapeutics Corporation Head and Neck 2024/11/20 $6,080,245*
DP250137 Revolutionizing Solid Tumor Therapy with Bispecific TCRm Antibodies Targeting Intracellular Cancer Targets Product Development Research Zha, Dongxing Ypsilon Therapeutics Breast, Lung and Bronchus, Stomach 2024/11/20 $2,727,500*
DP250140 A Phase 1 clinical trial of OR-449, a novel oral targeted therapy for pediatric and adult adrenocortical cancer patients Product Development Research Thacher, Scott Orphagen Pharmaceuticals, Inc. Endocrine, Head and Neck, Lung and Bronchus 2024/11/20 $10,213,909*
DP250142 Eisbach Bio - Clinical Development of the ALC1 DDR inhibitor EIS-12656 Product Development Research Schomburg, Adrian Eisbach Bio Inc. Breast, Ovary, Pancreas 2024/11/20 $4,750,000*
DP250143 TELOVANCE: A Transient Telomere Lengthening Platform Designed to Enhance the Expansion and Efficacy of Human Cell and Gene Therapies Product Development Research Sayed, Mohammed Telos Biotechnology Lymphoma, Myeloma, Skin 2024/11/20 $2,778,945*
DP250149 Functional assay of immunoproteasome for patient stratification to checkpoint inhibitor therapy using single-molecule protein sequencing Product Development Research Swaminathan, Jagannath Erisyon, INC Lung and Bronchus 2024/11/20 $2,157,173*
DP250150 A Phase 1 Study of Multi-Tumor Associated Antigen Specific T Cells (MT-601) in Patients with Metastatic Pancreatic Cancer following frontline FOLFIRINOX Product Development Research Vera, Juan Marker Therapeutics, Inc. Pancreas 2024/11/20 $9,513,569*
DP250157 Clinical Utility Study for the Commercial Launch of a Best-in-Class Liver Cancer Screening Blood Test for High-Risk Liver Disease Patients Product Development Research Patnaik, Ritish Curve Biosciences Gallbladder, Liver and Intrahepatic Bile Duct 2024/11/20 $11,340,000*
DP250159 (S)-TASIN-15 Phase 1 Dose Escalation, Optimization & RP2D Determination Product Development Research Thapar, Neil C Barricade Therapeutics, Corp. Colorectal 2024/11/20 $14,005,035*
PP250004 A Virtual, Centralized Lung Cancer Screening Program for Northeast Texas Prevention Minnix, Jennifer The University of Texas M.D. Anderson Cancer Center Lung and Bronchus 2024/11/20 $1,497,342

*Pending contract negotiation
1Any differences between announced award dollar amounts and current award dollar amounts are due to changes occurring during the contracting process, transfer of an award to a different organization or non-acceptance by recipient organization

Showing 1 to 10 of 2,037 entries